June 4, 2012
A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.
June 1, 2012
Cancer drug development is known to be too slow, costly and fraught with failure. Now the U.S. Food and Drug Administration is issuing recommendations for breast cancer trials that would substantially accelerate patient access to new medications while lowering the time and cost of drug development.
May 30, 2012
At one of the highest-ranked medical schools in the country, it’s not surprising to find students with big appetites for learning. In the laboratory, there are those who seek out challenges at the bench, peering into microscopes for answers.
May 4, 2012
It’s a real challenge to treat a patient with relapsed cancer, because the cancer has outsmarted initial treatment and has become more resistant, says Steven DuBois, MD, assistant professor of pediatrics at UCSF’s School of Medicine and a specialist in childhood cancers.
May 2, 2012
A pioneering approach to imaging breast cancer in mice has revealed new clues about why the human immune system often fails to attack tumors and keep cancer in check. This observation, by scientists at the University of California, San Francisco (UCSF), may help to reveal new approaches to cancer immunotherapy.
May 1, 2012
In a study of patients 65 and older with non-small-cell lung cancer (NSCLC), younger patients were more likely to receive treatment than older patients, regardless of overall health and prognosis.
April 26, 2012
UCSF Chancellor Susan Desmond-Hellmann, MD, MPH, announced a four-year $100 million fund-raising initiative during her April 24 speech marking the beginning of commencement season at the University.
April 17, 2012
A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients suffered from recurrent glioblastoma multiforme—which kills thousands of Americans every year.
April 16, 2012
The key to treating one of the most common types of human leukemia may lie within mutations in a gene called FLT3, according to new research led by physician-scientists at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.
April 10, 2012
Frank McCormick, PhD, FRS, director of the Helen Diller Family Comprehensive Cancer Center at UCSF, was elected president of the 35,000-member American Association of Cancer Research (AACR), the world’s largest organization of its kind dedicated to prevent and cure cancer through research, education, communication and collaboration.